{"id":"hexobendine","rwe":[{"pmid":"10856445","year":"2000","title":"Further characterization of an adenosine transport system in the mitochondrial fraction of rat testis.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"1528273","year":"1992","title":"[3H]R75231--a new radioligand for the nitrobenzylthioinosine sensitive nucleoside transport proteins. Characterization of (+/-)-[3H]R75231 binding to calf lung membranes, stereospecificity of its two stereoisomers, and comparison with [3H]nitrobenzylthioinosine binding.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"2280800","year":"1990","title":"The relationship between ionization and affinity of nucleoside transport inhibitors.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"2744094","year":"1989","title":"Subtypes of nucleoside transport inhibitory sites in heart: a quantitative autoradiographical analysis.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"3247287","year":"1988","title":"Limiting solubilities and ionization constants of sparingly soluble compounds: determination from aqueous potentiometric titration data only.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"}],"tags":[{"label":"hexobendine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel alpha subunits; brain (Types I, II, III)","category":"target"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"SCN3A","category":"gene"},{"label":"C01DX06","category":"atc"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ditrimin","offLabel":[],"synonyms":["hexobendine","ditrimin","ditrimine","ditrymine","hexabendin","hexabendine","hexobendin"],"timeline":[],"approvals":[],"brandName":"Ditrimin","ecosystem":[],"mechanism":{"target":"Sodium channel alpha subunits; brain (Types I, II, III)","targets":[{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","drugClass":"hexobendine","explanation":"Imagine your nerves are like electrical wires that send signals to different parts of your body. Sodium channels are like the switches that turn these signals on and off. Ditrimin blocks these switches to change the way your nerves send signals, which can affect how you feel and respond to stimuli.","oneSentence":"Ditrimin works by blocking sodium channels in the brain to modulate nerve impulses.","technicalDetail":"Ditrimin binds to the sodium channel alpha subunits, specifically types I, II, and III, to inhibit the flow of sodium ions and modulate the excitability of neurons."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1370","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEXOBENDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:53:08.130718","biosimilars":[],"competitors":[{"drugName":"nesiritide","drugSlug":"nesiritide","fdaApproval":"2001-08-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vericiguat","drugSlug":"vericiguat","fdaApproval":"2021-01-19","patentExpiry":"Nov 26, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hexobendine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nesiritide","brandName":"nesiritide","genericName":"nesiritide","approvalYear":"2001","relationship":"same-class"},{"drugId":"vericiguat","brandName":"vericiguat","genericName":"vericiguat","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166651","NDDF":"009790","UNII":"B6X4SYR93B","CHEBI":"CHEBI:135843","INN_ID":"1759","RXNORM":"5303","UMLSCUI":"C0019471","ChEMBL_ID":"CHEMBL127300","KEGG_DRUG":"D04438","DRUGBANK_ID":"DB13265","PUBCHEM_CID":"5777","SNOMEDCT_US":"710319000","MESH_DESCRIPTOR_UI":"D006592"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":108,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DX06","allCodes":["C01DX06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2000 Jun 9","pmid":"10856445","title":"Further characterization of an adenosine transport system in the mitochondrial fraction of rat testis.","journal":"European journal of pharmacology"},{"date":"1992 May","pmid":"1528273","title":"[3H]R75231--a new radioligand for the nitrobenzylthioinosine sensitive nucleoside transport proteins. Characterization of (+/-)-[3H]R75231 binding to calf lung membranes, stereospecificity of its two stereoisomers, and comparison with [3H]nitrobenzylthioinosine binding.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"1990 Sep","pmid":"2280800","title":"The relationship between ionization and affinity of nucleoside transport inhibitors.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"1989 Apr 12","pmid":"2744094","title":"Subtypes of nucleoside transport inhibitory sites in heart: a quantitative autoradiographical analysis.","journal":"European journal of pharmacology"},{"date":"1988 Dec","pmid":"3247287","title":"Limiting solubilities and ionization constants of sparingly soluble compounds: determination from aqueous potentiometric titration data only.","journal":"Pharmaceutical research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ditrimin (HEXOBENDINE) is a small molecule hexobendine drug that targets sodium channel alpha subunits in the brain, specifically types I, II, and III. It is not FDA-approved for any indications, and its commercial status, generic availability, and patent status are unknown. As a hexobendine, Ditrimin works by modulating sodium channels, which are crucial for the transmission of nerve impulses. The exact indications and safety profile of Ditrimin are unclear due to its lack of FDA approval. Further research is needed to determine its efficacy and potential side effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}